Improving Immunogenicity of Influenza Vaccine in HIV Infected Individuals
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT01262846|
Recruitment Status : Completed
First Posted : December 17, 2010
Results First Posted : April 13, 2017
Last Update Posted : April 13, 2017
|Condition or disease||Intervention/treatment||Phase|
|HIV Infection||Biological: Fluzone®||Phase 4|
|Study Type :||Interventional (Clinical Trial)|
|Actual Enrollment :||195 participants|
|Intervention Model:||Parallel Assignment|
|Masking:||Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|
|Official Title:||Improving Immunogenicity of Influenza Vaccine in HIV Infected Individuals|
|Study Start Date :||November 2010|
|Actual Primary Completion Date :||April 2011|
|Actual Study Completion Date :||April 2011|
Active Comparator: Fluzone SD
Fluzone® Standard dose
Fluzone® Standard dose in a blinded manner as single-0.5mL injection intramuscularly into one of the subject's deltoid muscles.
Experimental: Fluzone® High dose
Fluzone® High dose in a blinded manner as single-0.5mL injection intramuscularly into one of the subject's deltoid muscles.
Fluzone® High dose or Standard dose in a blinded manner as single-0.5mL injection intramuscularly into one of the subject's deltoid muscles.
- Immunogenicity [ Time Frame: Baseline to 21 days ]To compare the immunogenicity of trivalent Fluzone® High-Dose vaccine vs the regular standard-dose (SD) in HIV infected individuals.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01262846
|United States, Pennsylvania|
|Clinical Trials Unit. University of Pennsylvania|
|Philadelphia, Pennsylvania, United States, 19104--607|
|Principal Investigator:||PABLO TEBAS, MD||University of Pennsylvania|